MedTrace Logo

α-N-acetylgalactosaminidase Levels in Panic Disorder

NCT07424911 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2026-06-29

No results posted yet for this study

Summary

This prospective observational cohort study investigated serum α-N-acetylgalactosaminidase levels in drug-naïve patients with Panic Disorder (PD) at baseline and after six weeks of follow-up and compared them with healthy controls (HC). Associations between enzyme levels, symptom severity, and inflammatory markers were examined. The study aimed to evaluate whether α-N-acetylgalactosaminidase levels are associated with PD symptom severity and inflammatory parameters.

Conditions

Interventions

OTHER

No intervention was assigned as part of the research protocol.

No intervention was assigned as part of the research protocol.

Sponsors & Collaborators

  • Elazığ Mental Health and Diseases Hospital

    lead OTHER_GOV

Principal Investigators

  • Mehmet Hamdi ÖRÜM, MD · Elazığ Mental Health and Diseases Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2025-06-16
Completion
2025-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07424911 on ClinicalTrials.gov